OTCMKTS:KHTRF

Knight Therapeutics News Headlines

$4.33
+0.06 (+1.41 %)
(As of 05/10/2021 01:45 PM ET)
Add
Compare
Today's Range
$4.33
$4.34
50-Day Range
$3.99
$4.48
52-Week Range
$3.95
$5.59
Volume600 shs
Average Volume28,135 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Knight Therapeutics (OTCMKTS KHTRF) News Headlines Today

SourceHeadline
Knight Therapeutics (KHTRF) Outperform Rating Reiterated at Raymond JamesKnight Therapeutics' (KHTRF) Outperform Rating Reiterated at Raymond James
americanbankingnews.com - April 26 at 3:28 PM
Knight Therapeutics (OTCMKTS:KHTRF) PT Raised to $7.75 at KCGKnight Therapeutics (OTCMKTS:KHTRF) PT Raised to $7.75 at KCG
americanbankingnews.com - April 26 at 2:57 PM
Knight Therapeutics (KHTRF) "Buy" Rating Reiterated at Cannonball ResearchKnight Therapeutics' (KHTRF) "Buy" Rating Reiterated at Cannonball Research
americanbankingnews.com - April 26 at 1:48 PM
Knight Therapeutics (OTCMKTS:KHTRF) Price Target Increased to $7.75 by Analysts at Knight EquityKnight Therapeutics (OTCMKTS:KHTRF) Price Target Increased to $7.75 by Analysts at Knight Equity
americanbankingnews.com - April 26 at 12:12 PM
Knight Therapeutics to Acquire Regional Rights to Exelon®Knight Therapeutics to Acquire Regional Rights to Exelon®
benzinga.com - April 23 at 7:33 AM
Knight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor ConferenceKnight to Present at the 2021 Bloom Burton & Co. Healthcare Virtual Investor Conference
finance.yahoo.com - April 13 at 6:39 PM
Knight Therapeutics stock underperforms, disappoint faithfulKnight Therapeutics stock underperforms, disappoint faithful
theglobeandmail.com - April 1 at 7:57 AM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 27 at 1:37 AM
Heres what Wall Street expects from Knight Therapeuticss earningsHere's what Wall Street expects from Knight Therapeutics's earnings
markets.businessinsider.com - March 25 at 2:32 PM
Knight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with ConstipationKnight Therapeutics Announces Canadian Commercial Launch of IBSRELA™ - New Innovative Treatment for Irritable Bowel Syndrome with Constipation
finance.yahoo.com - March 1 at 7:15 PM
Rock star Growth Puts Knight Therapeutics (TSE:GUD) In A Position To Use DebtRock star Growth Puts Knight Therapeutics (TSE:GUD) In A Position To Use Debt
finance.yahoo.com - January 6 at 8:43 AM
Knight Announces Filing of Preliminary Base Shelf ProspectusKnight Announces Filing of Preliminary Base Shelf Prospectus
finance.yahoo.com - December 10 at 5:00 PM
Time To Worry? Analysts Are Downgrading Their Knight Therapeutics Inc. (TSE:GUD) OutlookTime To Worry? Analysts Are Downgrading Their Knight Therapeutics Inc. (TSE:GUD) Outlook
finance.yahoo.com - November 18 at 8:43 AM
Knight Therapeutics Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next YearKnight Therapeutics Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
finance.yahoo.com - November 17 at 12:32 PM
Estimating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)Estimating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)
finance.yahoo.com - November 16 at 3:24 PM
Knight Therapeutics Reports Third Quarter 2020 ResultsKnight Therapeutics Reports Third Quarter 2020 Results
finance.yahoo.com - November 13 at 7:40 AM
Notice of Knight Therapeutics Third Quarter 2020 Results Conference CallNotice of Knight Therapeutics' Third Quarter 2020 Results Conference Call
finance.yahoo.com - November 6 at 7:36 AM
Knight Therapeutics Inc. (KHTRF)Knight Therapeutics Inc. (KHTRF)
in.finance.yahoo.com - October 8 at 2:25 PM
Health Canada OKs Knight and TherapeuticsMD for BIJUVAHealth Canada OK's Knight and TherapeuticsMD for BIJUVA
seekingalpha.com - September 21 at 6:20 PM
Knight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast CancerKnight Therapeutics Announces Filling of Supplement to a New Drug Submission for NERLYNX® (neratinib) to Treat HER2-Positive Metastatic Breast Cancer
finance.yahoo.com - September 3 at 7:07 PM
Why Knight Therapeutics' (TSE:GUD) CEO Pay MattersWhy Knight Therapeutics' (TSE:GUD) CEO Pay Matters
finance.yahoo.com - August 18 at 2:13 PM
Knight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% OwnershipKnight Therapeutics Completes the Tender Offer for Grupo Biotoscana And Achieves Over 95% Ownership
markets.businessinsider.com - August 14 at 7:12 PM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q2 2020 Results - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 2:57 PM
Knight Therapeutics launches tender offer for 48.8% of Grupo BiotoscanaKnight Therapeutics launches tender offer for 48.8% of Grupo Biotoscana
seekingalpha.com - July 15 at 1:18 PM
Knight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo BiotoscanaKnight Therapeutics Announces the Launch of the Tender Offer for remaining 48.8% of Grupo Biotoscana
finance.yahoo.com - July 15 at 8:06 AM
Knight Therapeutics to buy back up to 10.9M sharesKnight Therapeutics to buy back up to 10.9M shares
seekingalpha.com - July 10 at 8:22 AM
Knight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo BiotoscanaKnight Therapeutics Announces CVM Approval of the Tender Offer for remaining 48.8% of Grupo Biotoscana
markets.businessinsider.com - July 8 at 6:48 PM
Need To Know: Analysts Just Made A Substantial Cut To Their Knight Therapeutics Inc. (TSE:GUD) EstimatesNeed To Know: Analysts Just Made A Substantial Cut To Their Knight Therapeutics Inc. (TSE:GUD) Estimates
finance.yahoo.com - July 1 at 7:44 AM
Knight Therapeutics (KHTRF) CEO Jonathan Ross Goodman on Q1 2020 Results - Earnings Call TranscriptKnight Therapeutics' (KHTRF) CEO Jonathan Ross Goodman on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - June 26 at 4:25 PM
Notice of Knight Therapeutics First Quarter 2020 Results Conference CallNotice of Knight Therapeutics' First Quarter 2020 Results Conference Call
www.benzinga.com - June 18 at 6:43 PM
Knight Therapeutics Ibsrela OKd in CanadaKnight Therapeutics' Ibsrela OK'd in Canada
seekingalpha.com - April 17 at 10:11 AM
Knight Therapeutics Inc. Announces Triumvira Loan RepaymentKnight Therapeutics Inc. Announces Triumvira Loan Repayment
www.benzinga.com - April 16 at 7:33 AM
How Does Knight Therapeutics's (TSE:GUD) P/E Compare To Its Industry, After Its Big Share Price Gain?How Does Knight Therapeutics's (TSE:GUD) P/E Compare To Its Industry, After Its Big Share Price Gain?
finance.yahoo.com - April 15 at 8:38 AM
Knight Therapeutics Files Annual Information FormKnight Therapeutics Files Annual Information Form
www.benzinga.com - April 9 at 10:56 PM
Knight Therapeutics (KHTRF) CEO Jonathan Ross Goodman on Q4 2019 Results - Earnings Call TranscriptKnight Therapeutics' (KHTRF) CEO Jonathan Ross Goodman on Q4 2019 Results - Earnings Call Transcript
seekingalpha.com - March 31 at 1:00 AM
How Much Are Knight Therapeutics Inc. (TSE:GUD) Insiders Spending On Buying Shares?How Much Are Knight Therapeutics Inc. (TSE:GUD) Insiders Spending On Buying Shares?
finance.yahoo.com - March 30 at 8:00 PM
TherapeuticsMD: Inside The NumbersTherapeuticsMD: Inside The Numbers
seekingalpha.com - February 11 at 12:51 AM
Health Canada to review Knights NDS for BijuvaHealth Canada to review Knight's NDS for Bijuva
seekingalpha.com - November 26 at 8:39 AM
BRIEF-Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their BusinessesBRIEF-Knight Therapeutics Inc Says Co, Medison Biotech (1995) Ltd Have Agreed To Separate Their Businesses
www.msn.com - November 21 at 10:59 PM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q3 2019 - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q3 2019 - Earnings Call Transcript
seekingalpha.com - November 12 at 10:53 PM
Knight to acquire Latin American pharma firm for C$369MKnight to acquire Latin American pharma firm for C$369M
seekingalpha.com - October 21 at 12:19 PM
Shares in Biotoscana, Knight Therapeutics up after deal announcementShares in Biotoscana, Knight Therapeutics up after deal announcement
finance.yahoo.com - October 21 at 12:19 PM
Knight Therapeutics to purchase Biotoscana in $281 million dealKnight Therapeutics to purchase Biotoscana in $281 million deal
ca.finance.yahoo.com - October 21 at 12:19 PM
UPDATE 1-Knight Therapeutics to purchase Biotoscana in $281 mln dealUPDATE 1-Knight Therapeutics to purchase Biotoscana in $281 mln deal
finance.yahoo.com - October 21 at 12:19 PM
Have Insiders Been Buying Knight Therapeutics Inc. (TSE:GUD) Shares?Have Insiders Been Buying Knight Therapeutics Inc. (TSE:GUD) Shares?
finance.yahoo.com - September 25 at 3:35 PM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q2 2019 - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q2 2019 - Earnings Call Transcript
seekingalpha.com - August 11 at 11:25 AM
Initial reimbursement set in Canada for Knights ProbuphineInitial reimbursement set in Canada for Knight's Probuphine
seekingalpha.com - August 6 at 10:50 AM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q1 2019 Results - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 10:12 AM
Knight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2018 Results - Earnings Call TranscriptKnight Therapeutics Inc. (KHTRF) CEO Jonathan Ross Goodman on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 15 at 10:57 AM
This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.